KRW 18200.0
(0.94%)
Year | Total Assets | Total Assets Growth |
---|---|---|
2023 | 72.83 Billion KRW | -17.9% |
2022 | 88.71 Billion KRW | 15.01% |
2021 | 77.13 Billion KRW | -6.45% |
2020 | 82.45 Billion KRW | 30.44% |
2019 | 63.21 Billion KRW | -1.3% |
2018 | 64.04 Billion KRW | 77.91% |
2017 | 36 Billion KRW | 8.73% |
2016 | 33.1 Billion KRW | 0.0% |
Year | Total Assets | Total Assets Growth |
---|---|---|
2024 Q2 | 66.95 Billion KRW | -5.78% |
2024 Q1 | 71.06 Billion KRW | -2.43% |
2023 FY | 72.83 Billion KRW | -17.9% |
2023 Q2 | 74.61 Billion KRW | -4.67% |
2023 Q3 | 73.96 Billion KRW | -0.87% |
2023 Q4 | 72.83 Billion KRW | -1.54% |
2023 Q1 | 78.27 Billion KRW | -11.77% |
2022 Q2 | 72.01 Billion KRW | -3.69% |
2022 FY | 88.71 Billion KRW | 15.01% |
2022 Q4 | 88.71 Billion KRW | 30.74% |
2022 Q3 | 67.85 Billion KRW | -5.77% |
2022 Q1 | 74.77 Billion KRW | -3.06% |
2021 Q3 | 78.85 Billion KRW | 0.0% |
2021 FY | 77.13 Billion KRW | -6.45% |
2021 Q4 | 77.13 Billion KRW | -2.18% |
2020 FY | 82.45 Billion KRW | 30.44% |
2019 FY | 63.21 Billion KRW | -1.3% |
2018 FY | 64.04 Billion KRW | 77.91% |
2017 FY | 36 Billion KRW | 8.73% |
2016 FY | 33.1 Billion KRW | 0.0% |
Name | Total Assets | Total Assets Difference |
---|---|---|
HLB Pharmaceutical Co., Ltd | 141.35 Billion KRW | 48.474% |
CMG Pharmaceutical Co., Ltd. | 186.85 Billion KRW | 61.021% |
Celltrion Pharm, Inc. | 641.64 Billion KRW | 88.649% |
Huons Global Co., Ltd. | 1317.96 Billion KRW | 94.474% |
DongKook Pharmaceutical Co., Ltd. | 839.53 Billion KRW | 91.325% |
Enzychem Lifesciences Corporation | 211.54 Billion KRW | 65.571% |
Humedix Co., Ltd. | 219.97 Billion KRW | 66.891% |
Boditech Med Inc. | 227.9 Billion KRW | 68.042% |
EuBiologics Co., Ltd. | 172.64 Billion KRW | 57.813% |
Huons Co., Ltd. | 537.28 Billion KRW | 86.444% |
BNC Korea Co., Ltd. | 236.15 Billion KRW | 69.158% |
AptaBio Therapeutics Inc. | 92.51 Billion KRW | 21.278% |